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Ecotropic murine leukemia virusRecently it has been reported that a cathepsin B inhibitor, CA-074Me, attenuates ecotropic murine leukemia
virus (Eco-MLV) infection in NIH3T3 cells, suggesting that cathepsin B is required for the Eco-MLV infection.
However, cathepsin B activity was negative or extremely low in NIH3T3 cells. How did CA-074Me attenuate
the Eco-MLV infection? The CA-074Me treatment of NIH3T3 cells inhibited cathepsin L activity, and a
cathepsin L speciﬁc inhibitor, CLIK148, attenuated the Eco-MLV vector infection. These results indicate that
the suppression of cathepsin L activity by CA-074Me induces the inhibition of Eco-MLV infection, suggesting
that cathepsin L is required for the Eco-MLV infection in NIH3T3 cells. The CA-074Me treatment inhibited the
Eco-MLV infection in human cells expressing the exogenous mouse ecotropic receptor and endogenous
cathepsins B and L, but the CLIK148 treatment did not, showing that only the cathepsin L suppression by
CLIK148 is not enough to prevent the Eco-MLV infection in cells expressing both of cathepsins B and L, and
CA-074Me inhibits the Eco-MLV infection by suppressing both of cathepsins B and L. These results suggest
that either cathepsin B or L is sufﬁcient for the Eco-MLV infection.
© 2009 Elsevier Inc. All rights reserved.Introduction
Ecotropic murine leukemia viruses (Eco-MLVs) recognize cationic
amino acid transporter 1 (CAT1) as the entry receptor (Albritton et al.,
1989). After the receptor recognition, the Eco-MLV particles are
internalized into endosomes, and then the virus core enters into host
cytoplasm by fusion between viral envelope and host cell endosomal
membrane. Themembrane fusion mediated by the Eco-MLV envelope
glycoprotein (Env) is activated by endosome acidiﬁcation (Katen et
al., 2001; McClure et al., 1990).
The Eco-MLV Env protein has the 16-amino acid peptide (R
peptide) at the C-terminal tail that inhibits the membrane fusion
reaction. The R peptide is cleaved during virion maturation to achieve
viral entry by the membrane fusion (Kubo and Amanuma, 2003; Kubo
et al., 2007; Ragheb and Anderson, 1994; Rein et al., 1994). The R
peptide-truncated Env protein induces syncytia in susceptible cells,
but the R peptide-containing Env protein does not. However, the R
peptide-containing Env protein successfully induces syncytia in rat XC).
epartment of Microbiology and
Organization, Nagoya Medical
ll rights reserved.and fu-1 cells (Jones and Risser, 1993; Wong, Yuen, and Kaufman,
1977). We have previously reported that treatment of XC cells with
tunicamycin, an N-linked glycosylation inhibitor, signiﬁcantly sup-
presses the syncytium formation of XC cells by the R peptide-
containing Env protein, but does not that by the R peptide-truncated
Env protein, suggesting that an unknown glycosylated cellular protein
is involved in the XC cell-speciﬁc syncytium formation by the R
peptide-containing Env protein (Kubo, Ishimoto, and Amanuma,
2003). Because XC and fu-1 cells were both derived from muscle
tissues, it was speculated that the cellular factor is also associatedwith
syncytium formation in myogenesis.
In order to identify a keymolecule for the XC cell-speciﬁc syncytium
formation by the R peptide-containing Env protein, we analyzed
expressions of several glycosylated proteins in XC and NIH3T3 cells
that are involved in myogenesis. Cathepsin B is a glycosylated protein,
and its expression is upregulated during early myoblast fusion and is
downregulated in myotubes. It has been reported that cathepsin B-
deﬁcient myoblast cells undergo differentiation with impaired cell
fusion (Gogos et al., 1996), and a cathepsin B inhibitor, CA-074Me,
inhibits L6 myoblast differentiation (Jane et al., 2002). We found that
cathepsin B was expressed in XC cells, but was undetectable in NIH3T3
cells. However, it has been reported that CA-074Me suppresses the Eco-
MLV infection in NIH3T3 cells (Kumar et al., 2007). In our experiments,
the compound also inhibited the Eco-MLV vector infection in NIH3T3
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infection in the cathepsin B-undetectable NIH3T3 cells?
There are many evidences showing that cathepsin proteases B and
L both participate in viral infections, including Ebola virus, paramyxo-
virus, coronavirus, and reovirus (Chandran et al., 2005; Ebert et al.,
2002; Pager andDutch, 2005; Qiu et al., 2006; Simmons et al., 2005). In
addition, CA-074Me inhibits both of cathepsins B and L (Alain et al.,
2007; Montaser, Lalmanach, and Mach, 2002). Therefore, cathepsin L
might be involved in the Eco-MLV infection in cathepsin B-undetect-
able NIH3T3 cells. To assess this possibility, we analyzed effects of a
cathepsin L speciﬁc inhibitor, CLIK148, on the Eco-MLV infection. We
found in this study that CLIK148 signiﬁcantly inhibits the Eco-MLV
infection in the cathepsin B-undetectable NIH3T3 cells, but does not in
cells expressing both of cathepsins B and L, showing that cathepsin L is
required for the Eco-MLV infection in the cathepsin B-undetectable
NIH3T3 cells, but not in cathepsin B-expressing cells. These results
show that either cathepsin B or L is sufﬁcient for the Eco-MLV infection.
Results
Cathepsin B inhibitor, CA-074Me, inhibits Eco-MLV infection
It has been reported that a cathepsin B inhibitor, CA-074Me,
attenuates the Eco-MLV infection (Kumar et al., 2007). To conﬁrm this
result, we analyzed the effects of CA-074Me on the Eco-MLV vectorFig. 1. A cathepsin B inhibitor, CA-074Me, inhibits Eco-MLV vector infection. (A) Transductio
cells. (B) Transduction titers of the Eco-MLV vector were measured in CA-074Me-pretreat
volume of DMSO are indicated. (C) Numbers of viable cells were counted, and relative valu
titers of VSV-G-pseudotyped MLV vector were measured in CA-074Me-pretreated NIH3T3 a
These experiments were repeated three times. Error bars indicate standard deviations. Asteinfection in mouse NIH3T3, rat XC, and human cells (293T, TE671, and
NP2) expressing mouse CAT1 (mCAT1). These cells were pretreated
with CA-074Me for 5 h, and were inoculated with the Eco-MLV vector
having the LacZ gene as a marker. As already reported (Kumar et al.,
2007), the CA-074Me treatment attenuated the Eco-MLV vector
transduction in a dose-dependent manner in all cell lines examined
(Figs. 1A and B), but did not signiﬁcantly affect cell viability (Fig. 1C).
The inhibitory effect of CA-074Me on the Eco-MLV vector infection
was statistically signiﬁcant by ANOVA and Tukey's test in all the cell
lines (pb0.05). The CA-074Me treatment moderately inhibited VSV-
G-pseudotyped MLV vector transduction (Fig. 1D) as already reported
(Kumar et al., 2007), but the inhibitory effect on the VSV vector
transduction was lower than that on the Eco-MLV vector transduction
(Figs. 1A and B). These results suggest that cathepsin B is required for
the Eco-MLV vector infection.
CA-074Me is a membrane-permeable form of CA-074. Treatment
of NIH3T3 and XC cells with the original CA-074 at 40 μM did not
affect the Eco-MLV vector infection (data not shown). This result
indicates that secreted cathepsin B is not involved in the Eco-MLV
infection.
Cathepsin B is undetectable in NIH3T3 cells
To assess whether cathepsin B is expressed in mouse NIH3T3, rat
XC, human 293T, and human TE671 cells, cathepsin B mRNAn titers of the Eco-MLV vector were measured in CA-074Me-pretreated XC and NIH3T3
ed human cells expressing mCAT1. Relative values to titers in cells treated with equal
es to the numbers of viable cells in DMSO-treated cells are indicated. (D) Transduction
nd TE671/mCAT1 cells. Relative values to titers in DMSO-treated cells were indicated.
risks indicate signiﬁcant differences compared with titers in DMSO-treated cells.
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(about 190 bp) was detected in XC, 293T, and TE671 cells, but was
not in NIH3T3 cells (Figs. 2A and B). These PCR conditions amplify
the 3′ cathepsin B protease domain sequence. Even if a cathepsin B
mRNA variant lacking this region is expressed, the product does not
have protease activity. The cathepsin B mRNA level of TE671 cells
was higher than that of 293T cells. Cathepsin L mRNA was detected
in NIH3T3 and XC cells by RT-PCR. These results indicate that
NIH3T3 cells express cathepsin L mRNA, but not the cathepsin B
mRNA.
To conﬁrm that the cathepsin B is not expressed in NIH3T3 cells,
cathepsin B activity was measured using the cathepsin B detection
reagent. When the reagent is digested by cathepsin B in cells, the
digested product generates red ﬂuorescence. Fluorescence strength of
293T cells was increased by incubation with the cathepsin B detection
reagent, but that of NIH3T3 cells was not (Fig. 2C). This result
indicates that cathepsin B activity is negative or extremely low inFig. 2. Expression of cathepsin B in target cells. (A) Expressions of mouse cathepsin B (upper
RT-PCR. (B) Expression of human cathepsin B mRNA in human 293T and TE671 cells was ana
size marker (left side of the panels). (C) Cathepsin B activity in living cells was analyzed by
ﬂuorescence intensities (MFIs) of the stained cells were measured by a ﬂow cytometer. Rela
indicated. (D and E) Cathepsin B activities of the CA-074Me-treated cells were measured by t
detection reagent for 1 h. Histograms are indicated in panel (D). Grey areas in upper panels
Open areas indicate cells treated with DMSO and stained with the cathepsin B detection rea
the cathepsin detection reagent. Relative values to MFI of DMSO-treated cells are also ind
standard deviations. Asterisks indicate signiﬁcant differences compared with MFI of the conNIH3T3 cells. Cathepsin B activity in TE671 cells wasmuch higher than
293T cells (Figs. 2C and D) consistent with the result of cathepsin B
mRNA detection by RT-PCR (Fig. 2B).
The CA-074Me treatment reduced the ﬂuorescence strength of
293T and TE671 cells stained with the cathepsin B detection reagent,
indicating that CA-074Me indeed inhibits cathepsin B activity in 293T
and TE671 cells (Figs. 2D and E). Cathepsin B activity was more
effectively inhibited by CA-074Me in 293T cells than in TE671 cells,
because 293T cells were treated with CA-074Me at higher concen-
tration (50 μM) than TE671 cells (25 μM). The ﬂuorescence strength of
NIH3T3 cells stained with the cathepsin B detection reagent was not
reduced by the CA-074Me treatment (40 μM), supporting that
cathepsin B activity is negative in NIH3T3 cells, although the CA-
074Me treatment at the same concentration signiﬁcantly reduced the
Eco-MLV vector transduction (Fig. 1A). These results suggest that CA-
074Me does not attenuate the Eco-MLV infection by suppressing
cathepsin B activity.panel) and cathepsin L (middle panel) mRNAs in NIH3T3 and XC cells were analyzed by
lyzed by RT-PCR. A Hind III-digested product of the λ phage DNA was used as molecular
incubation of cells with the cathepsin B detection reagent for indicated times. Means of
tive values to MFIs of cells incubated with the cathepsin B detection reagent for 0 h are
he cathepsin B detection reagent. The treated cells were incubated with the cathepsin B
indicate cells treated with DMSO and unstained with the cathepsin B detection reagent.
gent. Grey areas in lower panels indicate cells treated with CA-074Me and stained with
icated in panel (E). These experiments were repeated three times. Error bars indicate
trol cells.
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NIH3T3 cells
It has been reported that CA-074Me inhibits both of cathepsins B
and L (Alain et al., 2007; Montaser, Lalmanach, and Mach, 2002).Fig. 3. Involvement of cathepsin L in Eco-MLV vector infection. (A) NIH3T3 andmCAT1-
expressing TE671 (TE671/mCAT1) cells were pretreated with a cathepsin L inhibitor,
CLIK148. Transduction titers of the Eco-MLV vector were measured in the treated cells.
Relative values to titers in cells treated with equal volume of DMSO are indicated. (B)
Numbers of viable cells were measured, and relative values to numbers of viable cells in
DMSO-treated cells are indicated. (C) Transduction titers of VSV-G-pseudotyped MLV
vector in the pretreated cells were measured. Relative values to titers in DMSO-treated
cells are indicated. These experiments were repeated three times. Error bars indicate
standard deviations. Asterisks indicate signiﬁcant differences compared with values in
DMSO-treated cells.Therefore, inhibition of cathepsin L activity by CA-074Me could
attenuate Eco-MLV vector infection in NIH3T3 cells. To assess this
possibility, we analyzed effects of a cathepsin L speciﬁc inhibitor,
CLIK148 (Tsuge et al., 1999), on the Eco-MLV vector infection. NIH3T3
cells were pretreated with CLIK148 for 5 h, and inoculated with the
Eco-MLV vector. The CLIK148 treatment signiﬁcantly suppressed the
Eco-MLV vector transduction in dose-dependent manner in NIH3T3
cells (Fig. 3A, left panel). The inhibitory effect of CLIK148 on the Eco-
MLV vector infection in NIH3T3 cells was statistically signiﬁcant by
ANOVA (pb0.05). The treatment of NIH3T3 cells with CLIK148 did not
signiﬁcantly suppressed cell viability (Fig. 3B, left panel) and VSV-G-
pseudotyped MLV vector infection (Fig. 3C, left panel). These results
indicate that cathepsin L is required for the Eco-MLV infection in
cathepsin B-negative NIH3T3 cells.
In contrast to NIH3T3 cells, human TE671 cells expressed both of
cathepsins B and L analyzed by the cathepsin detection reagents (Figs.
2 and 4). The CLIK148 treatment at 1000 μMdid not attenuate the Eco-
MLV vector infection in mCAT1-expressing TE671 cells (TE671/
mCAT1) (Fig. 3A, right panel). The CLIK148 treatment of TE671/
mCAT1 cells at 2000 μM moderately inhibited the Eco-MLV (Fig. 3A,
right panel) and VSV-G vector (Fig. 3C, right panel) infections, and
additionally induced cell growth suppression (Fig. 3B, right panel).
The cell growth suppression by the CLIK148 treatment (2000 μM)
should result in the attenuation of MLV vector infection indepen-
dently of envelope proteins. Therefore, we could not conclude that
cathepsin L is required for the Eco-MLV infection in TE671 cells
expressing both of cathepsins B and L.
Cathepsin L activity in NIH3T3 cells was higher than that in TE671
cells (Fig. 4A). The CLIK148 treatment at 1000 μM indeed inhibited
cathepsin L activity in NIH3T3 and TE671 cells analyzed by the
cathepsin L detection reagent (Figs. 4B and C). The CA-074Me
treatment of NIH3T3 and TE671 cells also inhibited cathepsin L
activity, as already reported (Montaser, Lalmanach, and Mach, 2002).
The CLIK148 treatment of TE671 cells did not affect cathepsin B
activity (Fig. 4D) (Katunuma et al., 1999). Therefore, it is suggested
that the CA-074Me treatment attenuates the Eco-MLV infection by
inhibiting cathepsin L activity in NIH3T3 cells, and by inhibiting both
of cathepsin B and L in TE671 cells.
The above results indicate that cathepsin L is required for the Eco-
MLV infection in cathepsin B-undetectable NIH3T3 cells, but not in
cathepsin B-expressing TE671 cells, suggesting that either cathepsin B
or L is sufﬁcient for the Eco-MLV infection. To conﬁrm this result,
NIH3T3 cells were transduced by an MLV vector encoding a mouse
cathepsin B. However, cathepsin B-expressing NIH3T3 cells were not
obtained (data not shown), perhaps because of cathepsin B-induced
apoptosis (Conus and Simon, 2008; Guicciardi et al., 2001).
Cathepsin inhibitors do not affect Eco-MLV virion binding to target cells
We assessed whether the CA-074Me and CLIK148 treatments
affect the Eco-MLV vector binding to the target cells (Yoshii et al.,
2008). The CA-074Me treatment (25 μM) did not affect the vector
binding to the TE671/mCAT1 cells (Fig. 5A). Similarly the CA-074Me
(40 μM) and CLIK148 (1000 μM) treatments of NIH3T3 cells did not
affect the MLV vector binding (Fig. 5B). These results indicate that the
CA-074Me and CLIK148 treatments did not attenuate the Eco-MLV
infection by suppressing the Eco-MLV vector binding to the target
cells.
Discussion
Although cathepsin B activity was negative or extremely low in
NIH3T3 cells, the cathepsin B inhibitor, CA-074Me, signiﬁcantly
suppressed the Eco-MLV vector infection. The CA-074Me treatment
inhibited cathepsin L activity as already reported (Alain et al., 2007;
Montaser, Lalmanach, and Mach, 2002). A cathepsin L speciﬁc
Fig. 4. Effects of CLIK148 on cathepsin B and L activities in NIH3T3 and TE671 cells. (A) NIH3T3 and TE671 cells were incubated with the cathepsin L detection reagent for 0 or 1 h, and
MFIs of the cells were measured by a ﬂow cytometer. Relative values toMFIs of cells incubated for 0 h are indicated. (B and C) Cathepsin L activities of CA-074Me- or CLIK148-treated
cells were measured by the cathepsin L detection reagent. Histograms are indicated in panel (B). Closed areas indicate cells treated with DMSO and unstained with the cathepsin L
detection reagent. Open areas indicate cells treated with DMSO and stained with the reagent. Grey areas indicate cells treated with CLIK148 (middle panel) or CA-074Me (lower
panel) and stained with the reagent. Relative values to MFIs of DMSO-treated cells are also indicated in panel (C). (D) Cathepsin B activity of CLIK148-treated cells was measured by
the cathepsin B detection reagent. Relative values to MFIs of DMSO-treated cells are indicated in the left panel. Histogramwas indicated in the right panel. Closed area indicates cells
treated with DMSO and stained with the cathepsin B detection reagent. Red line indicates cells treated with CLIK148 and stained with the reagent. These experiments were repeated
three times. Error bars indicate standard deviations. Asterisks indicate signiﬁcant differences compared to values in the control cells.
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CLIK148 did not inhibit cathepsin B activity. These results indicate that
cathepsin L is required for the Eco-MLV infection in cathepsin B-undetectable NIH3T3 cells. In contrast, the CLIK148 treatment did not
inhibit the Eco-MLV infection in TE671/mCAT1 cells expressing both
of cathepsins B and L, indicating that cathepsin L is not required for
Fig. 5. Cathepsin inhibitors do not attenuate virus–cell interaction. TE671/mCAT1 (A) were treated with DMSO (upper panel) or CA-074Me (25 μM) (lower panel). NIH3T3 cells (B)
were treated with DMSO (upper panel), CA-074Me (40 μM) (middle panel), or CLIK148 (1000 μM) (lower panel). Black area indicates cells suspended with culture supernatant of
TELCeB6 cells that do not express any Env proteins. Open area indicates cells suspended with culture supernatant of the Eco-MLV Env-expressing TELCeB6 cells.
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Therefore, it is suggested that either cathepsin B or L is sufﬁcient for
the Eco-MLV infection.
The CA-074Me treatment of NIH3T3 cells at 40 μM induced 90%
reduction in the Eco-MLV vector infection. The CLIK148 treatment at
much higher concentration (1000 μM) induced similar reduction in
the infection. CA-074Me is a membrane-permeable form of CA-074.
The CA-074 treatment at the same concentration (40 μM) did not
affect the Eco-MLV vector infection. Because CLIK148 is not mem-
brane-permeable like CA-074, much higher concentration of CLIK148
was needed to attenuate the Eco-MLV infection than membrane-
permeable CA-074Me.
The CA-074Me treatment of NIH3T3 and TE671 cells at 40 and 25
μM, respectively, resulted in 90% reduction in the Eco-MLV vector
infection. NIH3T3 cells needed higher concentration of CA-074Me to
attenuate the Eco-MLV infection than TE671 cells. Cathepsin B activity
was undetectable in NIH3T3 cells, but cathepsin L activity in NIH3T3
cells was higher than that in TE671 cells. Because CA-074Me
attenuates the Eco-MLV infection by inhibiting both of cathepsins B
and L, CA-074Me concentration required to attenuate the Eco-MLV
infection should be affected by total activities of cathepsins B and L.
The CLIK148 treatment moderately reduced cathepsin L activity to
50% of that in DMSO-treated cells. The CA-074Me treatment slightly
reduced cathepsin B activity to 80% of that in DMSO-treated cells. In
contrast, these treatments induced signiﬁcant reduction (90%) in the
Eco-MLV vector infection. When undiluted Eco-MLV vector solution
was inoculated into target cells, about 2×106 infected cells were
detected in DMSO-treated cells per culture dish. Because 2×105
infected cells were still detected in the inhibitor-treated cells, it is not
suspicious that cathepsin B activity of the target cells correlates to
susceptibility to the Eco-MLV infection.The CLIK148 treatment of NIH3T3 cells at 50 μM rather slightly
increased the Eco-MLV vector infection. A part of the Eco-MLV vector
particles could be degraded by cathepsin L in NIH3T3 cells expressing
cathepsin L at high level. The CLIK148 treatment at 50 μMcould inhibit
the degradation of vector particles but could not attenuate the Eco-
MLV infection. Therefore, the CLIK148 treatment at low concentration
could increase the Eco-MLV infection.
The CA-074Me treatment at 40 μM and the CLIK148 treatment at
1000 μM both induced 90% reduction in the Eco-MLV vector infection
in NIH3T3 cells, whereas the CLIK148 treatment more efﬁciently
inhibited cathepsin L activity in NIH3T3 cells than the CA-074Me
treatment did. It seems to be inconsistent that the CA-074Me
treatment less efﬁciently inhibits cathepsin L activity than the
CLIK148 treatment but these treatments attenuate the Eco-MLV
infection at similar extent. Therefore, CA-074Me might inhibit other
proteases that are involved in the Eco-MLV infection.
Cathepsin B activity was negative or extremely low in NIH3T3
cells. It has been reported that cathepsin B is required for reovirus-
mediated oncolysis, and transformed NIH3T3 cells are susceptible to
the reovirus-mediated oncolysis, but normal NIH3T3 cells are not
(Alain et al., 2007). Cathepsin B expression is signiﬁcantly (more than
50 times) elevated by transformation of NIH3T3 cells (Chambers et al.,
1992; He et al., 2004). These results suggest that cathepsin B activity
in normal NIH3T3 cells is negative or much lower than that in
transformed NIH3T3 cells, consistent with our result.
Cathepsin B is involved in syncytium formation during myogenesis
(Gogos et al., 1996; Jane et al., 2002), and is expressed in XC cells in
which the R peptide-containing Env protein can induce syncytium
formation (Jones and Risser, 1993; Kubo, Ishimoto, and Amanuma,
2003). As mentioned above, cathepsin B expression is signiﬁcantly
activated in transformed NIH3T3 cells (Chambers et al., 1992; He et al.,
233H. Yoshii et al. / Virology 394 (2009) 227–2342004). It has been reported that transformed NIH3T3 cells are highly
susceptible to the Eco-MLV particle-induced syncytium formation
compared to control NIH3T3 cells (Wilson, Marsh, and Eiden, 1992).
The activation of cathepsin B by the cellular transformation could confer
NIH3T3 cells more susceptible to the Eco-MLV particle-induced
syncytium formation. However, cathepsin B is not a determinant
molecule for the XC cell-speciﬁc syncytium formation induced by the R
peptide-containing Env protein, because the R peptide-containing Env
protein could not induce syncytia in transformedNIH3T3, 293T/mCAT1,
and TE671/mCAT1 cells expressing cathepsin B (data not shown).
Further study is needed to understand the mechanism by which the R
peptide-containing Env protein induces syncytia in XC cells.
In conclusion, cathepsin L is required for the Eco-MLV infection in
cathepsin B-undetectable NIH3T3 cells, but is not in cathepsin B-
expressing cells. CA-074Me attenuated the Eco-MLV infection by
inhibiting both of cathepsins B and L. These results suggest that either
cathepsinBor L is sufﬁcient for the Eco-MLV infection. This studypresents
the novel ﬁnding that cathepsin B is not the only protease involved in the
Eco-MLV infection, and cathepsin L also participates in the infection.
Materials and methods
Cells
Human 293T (Pear et al., 1993), TE671, TELCeB6 (Cosset et al.,
1995), NP2 (Soda et al., 1999), mouse NIH3T3, and rat XC (Kubo,
Ishimoto, and Amanuma, 2003) cells were cultured in Dulbecco's
modiﬁed Eagle's medium (Wako, Osaka, Japan) supplemented with
8% fetal bovine serum (Biosource, Rockville, MD) at 37 °C in 5% CO2.
Friend Eco-MLV vector-producing cells were constructed by stable
transfection of TELCeB6 cells with the Friend MLV Env expression
plasmid (Kubo et al., 2004). Ecotropic MLV receptor-expressing 293T,
TE671, and NP2 cells were constructed by a mCAT1-encoding MLV
vector as already reported (Kubo, Ishimoto, and Amanuma, 2003).
Semi-quantitative RT-PCR of cathepsin mRNAs
Total RNA samples were isolated by the TRIzol Reagent (Invitro-
gen, Carlsbad, CA). First strand cDNA was synthesized by a reverse-
transcriptase (RT) using random primers (TaKaRa, Otsu, Japa).
Polymerase chain reaction (PCR) was performed to measure mRNA
levels of cathepsins B and L using the LA Taq DNA polymerase
(TaKaRa). Nucleotide sequences of PCR primers for mouse cathepsin B
mRNA detection are 5′-GTA TAC AAG CAT GAAGCC GGT-3′ and 5′-TCA
AGT CCC AGC AGA TTA-3′. Nucleotide sequences of PCR primers for
human cathepsin BmRNA detection are 5′-GTG TAC CAA CAC GTC ACC
GGA-3′ and 5′-CAG GCC CAC GGC AGA TTA-3′. The PCR products were
subjected to NuSieve agarose gel electrophoresis (TaKaRa) for
separation of low molecular weight DNA fragments. Nucleotide
sequences of PCR primers for mouse cathepsin L mRNA detection
are 5′-ACT ATGAAC CCA ACT GTA GCA-3′ and 5′-TCA ATT CAC GAT
AGG ATA GCT-3′. GAPDHmRNA levels were also measured by RT-PCR
as controls (Kubo et al., 2008). The PCR products of cathepsin L and
GAPDH were subjected to standard agarose gel electrophoresis.
Transduction assay
Target cells (2×105) were plated onto a 6-cm culture dish, and
cultured for 24 h. The cells were treated with CA-074Me (Sigma, St.
Louis, MO) or CLIK148 (Tsuge et al., 1999) for 5 h. The cells were
washed to remove the inhibitor. VSV-G-pseudotyped MLV vector was
constructed by transient transfection of TELCeB6 cells by a VSV-G
expression plasmid. Culture supernatants of the vector-producing
cells were inoculated into the treated cells in the presence of
polybrene (Sigma) (4 μg/ml). When undiluted culture supernatant
of the Eco-MLV vector-producing cells was inoculated, numbers ofinfected cells were too many to count. Therefore, the culture
supernatant was diluted 1000 times with fresh medium and
inoculated into target cells. Two days after inoculation, the cells
were stained with 5-bromo-4-chloro-3-indolyl-β-D-galactopyrano-
side (X-Gal) (Wako). Numbers of blue cells were counted in randomly
selected 10 microscopic ﬁelds per dish. Usually 30–100 infected cells
were detected in a microscopic ﬁeld. Total numbers of infected cells in
10 microscopic ﬁelds were compared.
Cell viability
Target cells were treated with CA-074Me or CLIK148 for 5 h, and
were cultured for additional 5 h in a fresh medium. The cells were
collected and treated with trypan blue. Numbers of unstained cells
were counted using a counting chamber to estimate cell viability.
Cathepsin activity measurement in living cells
Cells were stained with the cathepsin B or L detection reagent (Cell
Technology, Minneapolis, MN). The reagent utilizes ﬂuorophore cresyl
violet that is bi-substituted by an amide linkage to a peptide that
contains a cathepsin B or L target cleavage sequence. In this form, the
cresyl violet leaving group is non-ﬂuorescent. Following cleavage at the
amide linkage site by the cathepsin protease B or L in living cells, the
mono and non-substituted cresyl violet ﬂuorophores generate red
ﬂuorescence. The stained cells were subjected to a ﬂow cytometer (BD
Biosciences, San Jose, CA) to measure ﬂuorescence strength of the cells.
MLV vector binding assay
A MLV vector binding assay was performed as reported previously
(Lavillette et al., 2000; Yoshii et al., 2008). Cells (1×106) were incubated
with the Eco-MLV vector solution for 1 h at 4 °C, and unbound vectorwas
removedby twowasheswithPBS.Vector–cell complexeswere incubated
sequentially at 4 °C with goat anti-MLV SU antiserum and then with PE-
conjugated anti-goat IgG (Jackson Laboratories). Fluorescence intensity
of the cells was analyzed by a ﬂow cytometer (BD Biosciences).
Statistical analysis
Differences between two groups of data were determined by
Student's t-test. Additionally, the effects of cathepsin inhibitors on the
Eco-MLV vector infection were evaluated using analysis of variance
(ANOVA) and Tukey's test. Statistical signiﬁcance was set at pb0.05
for all tests. The statistical analysis was performed using the SPSS
v15.0 software (SPSS Japan, Tokyo, Japan).
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